Scientists May Need to Rethink How Genomics Impacts Risk for OCD
Results of Mount Sinai-led study highlights the contribution of rare differences in an individual’s DNA sequences to disease risk
Both rare and commonly observed differences in the DNA letters strung along a person’s chromosomes can explain about a third of the risk for being diagnosed with obsessive-compulsive disorder (OCD), according to a new study led by scientists at the Icahn School of Medicine at Mount Sinai.
The researchers analyzed the genomic data of more than 2,000 Swedish-born individuals diagnosed with OCD. Their results, published in the American Journal of Psychiatry, may alter not only how scientists view the role that genomics plays in OCD but also how new treatments might be developed.
The study was led by scientists in the laboratory of Dorothy Grice, MD, Professor of Psychiatry at Icahn Mount Sinai.
Affecting about two percent of Americans, OCD describes a set of potentially life-long and debilitating symptoms, most notably intense and distressing recurring thoughts and actions. Although scientists have yet to find the exact causes of OCD, several studies indicate that multiple genomic and environmental factors may play a role in the disease. For instance, it has been estimated that anywhere between 25 to 50 percent of the risk for OCD behaviors may be attributable to genomic differences between individuals in a population.
Led by Behrang Mahjani, PhD, a researcher in Dr. Grice’s lab, the researchers compared the single nucleotide polymorphisms (SNPs)—the minor DNA spelling differences normally found in a person’s chromosomes—of 2,090 Swedish-born OCD patients with that of 4,567 controls, making it the largest study of its kind to date. Initial results supported previous studies. About 29 percent of the risk for OCD was attributed to differences in SNPs between patients and control subjects and about 90 percent of these differences are commonly observed throughout the general population. However, the researchers also found that about 10 percent of the risk could be linked to rare genomic differences, which were not seen in previous studies. Further analysis showed that the OCD-related SNPs were distributed across patients’ chromosomes, suggesting that multiple genomic differences combine to influence risk. Overall the results support the idea that OCD risk may, in part, be driven by randomly occurring changes to the entire genome rather than a few naturally selected “hot spots.” The researchers concluded that this new view of OCD highlights the important role of rare genomic differences in the risk of OCD, and may alter how scientists study the disorder to develop new treatments for patients.
Who: Behrang Mahjani, PhD, instructor, Department of Psychiatry at Icahn Mount Sinai; Dorothy Grice, MD, Professor of Psychiatry at Icahn Mount Sinai.
This study was supported by the National Institutes of Health (MH124679, MH057881, MH110427, MH120170, MH119084, and MH109528); the Friedman Brain Institute; the Beatrice and Samuel A. Seaver Foundation; the Mindworks Charitable Lead Trust; the Stanley Center for Psychiatric Research; the Swedish Research Council (2015-02271, 2018-02487, 538-2013-8864); the Center for Innovative Medicine (Sweden); the Klarman Family Foundation, the Brain and Behavior Research Foundation; and the Lundbeck Foundation (R276-2018-4581).
Behrang, M., Klei, L., Mattheison, M. et al., The genetic architecture of obsessive-compulsive disorder: alleles across the frequency spectrum contribute liability to OCD. American Journal of Psychiatry, November 18, 2021, DOI:10.1176/appi.ajp.2021.21010101.
About the Mount Sinai Health System
Mount Sinai Health System is one of the largest academic medical systems in the New York metro area, with more than 43,000 employees working across eight hospitals, over 400 outpatient practices, nearly 300 labs, a school of nursing, and a leading school of medicine and graduate education. Mount Sinai advances health for all people, everywhere, by taking on the most complex health care challenges of our time — discovering and applying new scientific learning and knowledge; developing safer, more effective treatments; educating the next generation of medical leaders and innovators; and supporting local communities by delivering high-quality care to all who need it.
Through the integration of its hospitals, labs, and schools, Mount Sinai offers comprehensive health care solutions from birth through geriatrics, leveraging innovative approaches such as artificial intelligence and informatics while keeping patients’ medical and emotional needs at the center of all treatment. The Health System includes approximately 7,300 primary and specialty care physicians; 13 joint-venture outpatient surgery centers throughout the five boroughs of New York City, Westchester, Long Island, and Florida; and more than 30 affiliated community health centers. We are consistently ranked by U.S. News & World Report's Best Hospitals, receiving high "Honor Roll" status, and are highly ranked: No. 1 in Geriatrics and top 20 in Cardiology/Heart Surgery, Diabetes/Endocrinology, Gastroenterology/GI Surgery, Neurology/Neurosurgery, Orthopedics, Pulmonology/Lung Surgery, Rehabilitation, and Urology. New York Eye and Ear Infirmary of Mount Sinai is ranked No. 12 in Ophthalmology. U.S. News & World Report’s “Best Children’s Hospitals” ranks Mount Sinai Kravis Children's Hospital among the country’s best in several pediatric specialties.